Recent developments include strategic acquisitions and partnerships, product launches, and legal outcomes that reflect ongoing efforts to expand and protect the business.

• In January 2026, Vystar submitted a binding letter of intent to acquire a stake in GoPaid.com LLC and form a strategic partnership with Capital R3alm to launch the R3alm Oracle and Collectibles platform [N2][N1].
• In December 2025, Vystar reported a court victory awarding $497,439.58 in legal fees and costs against EMA Financial, Inc. [N3].
• Vystar’s Vytex Cloud Bed-in-a-Box product was made available for sale in October 2025 and sales were restarted in September 2025 [N4][N5].
• In July 2025, Vystar introduced a new RxAir-800 replacement cartridge with an extended life UV-C bulb [N6].
• Also in July 2025, the company introduced an ultrasoft latex mattress topper with Vytex 55 density latex into its online store [N7].
• The Second Circuit affirmed dismissal of a complaint against Vystar in the case of EMA Financial LLC v. Vystar Corp. in July 2025 [N8].

Vystar's innovative Vytex technology addresses allergenic concerns in natural rubber latex products, potentially appealing to manufacturers and consumers seeking safer, eco-friendly materials. The FDA clearance of RxAir products and ongoing product development, including new replacement cartridges and bedding products, demonstrate active product innovation. Strategic partnerships and acquisitions, such as the stake in GoPaid.com LLC and collaboration with Capital R3alm, indicate efforts to diversify and expand market presence. The company's patent portfolio and legal victories support its competitive positioning.

Vystar faces significant liquidity constraints with a low current ratio and limited cash resources as of the latest filings. The company operates with only one employee, indicating limited operational scale. Its revenue is low and inconsistent, with net losses reported, reflecting challenges in achieving profitability. The markets for natural rubber latex and air purification are highly competitive and fragmented, with synthetic alternatives and numerous competitors. Regulatory approvals for end products using Vytex latex depend on third-party manufacturers, adding uncertainty. The company’s ability to raise additional capital and sustain operations remains a key risk.

Vystar's moat is based on its proprietary, multi-patented Vytex natural rubber latex technology that offers ultra-low protein latex, differentiating it in the natural rubber latex market. The company also holds FDA clearances for its RxAir air purification products, providing regulatory credibility. Its portfolio of patents and trademarks across multiple jurisdictions supports intellectual property protection. However, the company operates in highly competitive and fragmented markets with synthetic alternatives and faces challenges in market acceptance and regulatory approvals for end products using its raw materials.

• Liquidity and Capital Constraints: As of December 31, 2025, Vystar had limited cash and equivalents and a current ratio of 0.05, indicating potential challenges in meeting short-term obligations and financing operations.
• Market Acceptance and Competition: The company’s Vytex technology depends on acceptance by manufacturers and consumers in competitive markets with synthetic alternatives. RxAir competes in a fragmented air purification market with many players.
• Regulatory and Approval Risks: FDA clearance is required for end products using Vytex latex, but Vystar is not the applicant; reliance on third-party manufacturers for approvals introduces uncertainty.
• Operational Scale and Workforce: With only one employee reported as of December 31, 2025, operational capacity and scalability may be limited.
• Dependence on Third-Party Manufacturers and Partners: Vystar relies on third-party producers for manufacturing Vytex latex and RxAir products, which may face production or quality control issues.

• Vystar Corp is a Georgia corporation based in Worcester, Massachusetts, incorporated in 2003, with predecessor formed in 2000 [S1].
• The company owns and manufactures multiple brands of eco-friendly products for home, office, and medical sectors, focusing on three main brands: Vytex, RxAir, and Fluid Energy Conversion (FEC) [S1].
• Vystar had majority ownership in Murida Furniture Co., Inc. dba Rotmans Furniture, which ceased operations at end of 2022 and is reported as discontinued operations [S1].
• Vytex is Vystar's proprietary, multi-patented technology producing ultra-low protein natural rubber latex (NRL) that reduces antigenic and total protein to virtually undetectable levels, used in over 40,000 products including medical gloves, condoms, balloons, foams, textiles, adhesives, and bedding products like mattresses and pillows [S1].
• Vystar expanded Vytex into consumer bedding products by partnering with foam manufacturers to create mattresses, toppers, and pillows [S1].
• RxAir is a manufacturer of air purification systems using patented ViraTech UV light technology that destroys over 99% of airborne bacteria, viruses, and microorganisms, with products FDA certified as Class II medical devices and independently tested by EPA and FDA-certified labs [S1].
• RxAir product line includes residential filterless air purifiers and hospital-grade HEPA filtration products, sold online and through third-party distributors [S1].
• Fluid Energy Conversion (FEC) is a green energy segment focused on patented technologies involving fluid mechanics and thermodynamics, including the Hughes Reactor patent acquired in 2019, intended to enhance RxAir purification systems [S1].
• Vystar acquired assets of UV Flu Technologies in 2018 to create RxAir division and acquired NHS Holdings in 2018 to move into direct product offerings made from Vytex latex [S1].
• In December 2020, Vystar selected Corrie MacColl Limited as exclusive global partner for market development and distribution of Vytex deproteinized latex [S1].
• Vystar competes in highly fragmented markets for residential air purification and natural rubber latex products, facing competition from multinational and regional manufacturers and synthetic latex alternatives [S1].
• Vystar holds a portfolio of patents and trademarks in the U.S. and foreign countries and is committed to protecting its intellectual property [S1].
• The company is not subject to direct governmental regulation beyond general business laws; its RxAir400 product is FDA cleared as a Class II medical device, which provides market credibility [S1].
• As of December 31, 2025, Vystar had one employee [S1].
• Financial snapshot as of December 31, 2025: cash and equivalents $154,424; short-term investments $127,910; current assets $374,024; current liabilities $6,988,193; current ratio 0.05; cash ratio 0.04 [S2].
• For the year ended December 31, 2025, Vystar reported a net loss of $1,531,658 [S2].
• Basic and diluted EPS was -$0.03 for the quarter ended September 30, 2024 [S2].
• Revenue data is limited and dated; the latest available quarterly revenue figures show low sales volumes (e.g., $11,615 for Q2 2025) with gross profit margins fluctuating [S2].
• Vystar announced a binding letter of intent to acquire a stake in GoPaid.com LLC and form a strategic partnership with Capital R3alm to launch R3alm Oracle and Collectibles platform in January 2026 [N2][N1].
• The company reported a court victory awarding $497,439.58 in legal fees and costs against EMA Financial, Inc. in December 2025 [N3].
• Vystar’s Vytex Cloud Bed-in-a-Box product was made available for sale in October 2025 and sales were restarted in September 2025 [N4][N5].
• Vystar introduced a new RxAir-800 replacement cartridge with extended life UV-C bulb in July 2025 [N6].
• The company introduced an ultrasoft latex mattress topper with Vytex 55 density latex into its online store in July 2025 [N7].
• The Second Circuit affirmed dismissal of a complaint against Vystar in the case of EMA Financial LLC v. Vystar Corp. in July 2025 [N8].